Interagency Autism Coordinating Committee Strategic Plan for Autism Spectrum Disorder Research – 2012 UpdateSkip Over Navigation Links
(PDF – 1 MB)
- Question 1: When Should I Be Concerned?
- Question 2: How Can I Understand What Is Happening?
- Question 3: What Caused This to Happen and Can It Be Prevented?
- Question 4: Which Treatments and Interventions Will Help?
- Question 5: Where Can I Turn for Services?
- Question 6: What Does the Future Hold, Particularly for Adults?
- Question 7: What Other Infrastructure and Surveillance Needs Must Be Met?
- About the IACC
- IACC Member Roster
- Strategic Plan Update External Planning Group Members
- Office of Autism Research Coordination (OARC) Staff List
Question 3: What Caused This to Happen and Can It Be Prevented?
What Is New in This Research Area, and What Have We Learned in the Past Two Years?
Over the past two years, progress has been made in identifying genetic and environmental risk factors associated with ASD. Furthermore, there is a greater understanding of the mechanisms by which these factors may be acting to increase susceptibility for autism.
Genetic Risk Factors
The past two years have seen an explosion of research on genomic factors associated with autism, with more than 900 papers on "autism and genetics" listed in the National Library of Medicine's (NLM) PubMed database in 2011 and 2012. Progress in genomics has been enabled by the advent of rapid, inexpensive, precise sequencing tools and the availability of large repositories of DNA samples. At the time of the publication of the initial IACC Strategic Plan for ASD Research in 2009, most ASD-related genomic research was focused on finding common variants in the genome, which are believed to act in an additive fashion to increase risk for ASD. While these common variants are still of interest, recent research has mapped out three new areas for understanding ASD risk.
First, there are as many as 1,000 rare changes in DNA structure or sequence that contribute to ASD risk (Coe, Girirajan & Eichler, 2012; Neale et al., 2012; O'Roak et al., 2012b; Sanders et al., 2012). Sometimes these changes involve duplications or deletions of more than a million nucleotide bases (the building blocks of DNA), while at other times only a few bases are altered; however, the result in either case can be increased risk for ASD.
Second, these changes are frequently spontaneous, or de novo, arising in sperm or eggs prior to or just after conception (Iossifov et al., 2012). That is, if tested, neither parent would show these mutations in body cells such as their blood cells, but the mutations could be found in reproductive cells, such as the father's sperm cells, which divide throughout life.
Third, most of the genetic loci, or regions in the DNA, that are implicated in ASD are not specific to ASD. These include neurodevelopmental loci that also confer risk for other brain disorders such as schizophrenia, epilepsy, and attention deficit hyperactivity disorder (ADHD), as well as loci for intellectual deficit syndromes (Malhotra & Sebat, 2012). While rare and not specific to ASD, the same genomic changes are found repeatedly (O'Roak et al., 2012a).
Risk Factors Converge on Biological Pathways
This complex picture of multiple, nonspecific, spontaneously-arising genetic factors is beginning to converge on a few biological pathways, particularly signaling pathways that stabilize activity at synapses (junctions between neurons) in the brain (Devlin & Scherer, 2012; Malhotra & Sebat, 2012; Veltman & Brunner, 2012; Zoghbi & Bear, 2012). However, synaptic genes are not the entire story. In 2012, two genes associated with metabolic disorders were identified as potential contributors to autism risk. These genes code for enzymes involved in producing and maintaining normal levels of two types of amino acids, carnitine and branch chain amino acids, which are necessary for normal metabolism (Celestino-Soper et al., 2012; Novarino et al., 2012).
While genomic factors were estimated to account for up to 10% of autism cases in 2009, the most recent studies, based on whole exome sequencing, find currently identifiable genomic variants and mutations in 25% of cases (Devlin & Scherer, 2012; Sanders et al., 2012).
These complex results present major challenges, not only in understanding causes of autism, but also in identifying treatments that will be effective for a large fraction of cases. "Autism" is likely several etiologically distinct disorders (disorders with different sets of causal factors) that converge to create a common set of behavioral deficits. Moreover, there is already considerable evidence that the multiple autism genetic risk genes converge on a smaller number of biological mechanisms, suggesting that it may be possible to treat many types of autism by targeting common underlying biological pathways, as opposed to requiring a specific treatment for each different mutation.
Environmental Risk Factors
The complexity of autism risk necessitates research on the interface between genomics and environmental exposures, including research on how biotic (e.g., dietary factors) and xenobiotic (e.g., exposures to drugs and environmental toxicants) factors may interact with genetic susceptibility. New research has emphasized the role of non-genomic risk factors. The largest U.S. twin study compared the concordance rates (the likelihood that both twins share an ASD diagnosis) in identical (monozygotic) twins, who share 100% of their DNA, and fraternal (dizygotic) twins, who share 50% of their DNA. In contrast to earlier, higher estimates, the ASD concordance rate for male identical twins was 77% (58% for strict autism, a smaller subset of ASD) and for male fraternal twins was 31% (21% for strict autism) (Hallmayer et al., 2011). The lower concordance rate for identical twins in this study compared to the rates identified in previous studies suggested that genomic factors (including spontaneous mutations) might be less important than previously claimed from twin studies. In addition, since the concordance rate in fraternal twins was considerably higher than the traditional figure of 3% to 10% estimated for siblings, the study appeared to support the importance of the prenatal environment, which is shared by fraternal twins but not by non-twin siblings.
A recent report from the Baby Siblings Research Consortium, however, challenged the previously mentioned traditional figure of a 3% to 10% recurrence rate in siblings. The study, using a larger sample size and updated methodology, suggests that the non-twin male sibling rate of developing ASD is 26.2%, which is in the range of concordance for male fraternal twins (Ozonoff et al., 2011). Thus, the rate of autism in fraternal twin siblings and in non-twin siblings may be more similar than previously thought.
A list of candidate environmental exposures identified for future study was developed in a 2010 workshop of experts supported by the National Institute of Environmental Health Sciences (NIEHS) and Autism Speaks. The list, published in 2012, included: lead, methylmercury, polychlorinated biphenyls (PCBs), organophosphate, pyrethroid, organochlorine insecticides, endocrine disruptors, automotive exhaust, polycyclic aromatic hydrocarbons, brominated flame retardants, and perfluorinated compounds (Landrigan, Lambertini & Birnbaum, 2012). These compounds are widely distributed within the environment and have known neurodevelopmental effects that may be relevant to autism. For example, insecticides are known to target neurotransmitter systems known to be impaired in autistic children (Roberts et al., 2007; Shelton, Hertz-Picciotto & Pessah, 2012). Within the past year, developmental exposure to specific types of PCBs (compounds used in many industrial applications such as insulators, coolants, and plasticizers) in rodents was reported to alter activity-dependent growth of neuron dendrites by mechanisms implicated in autism (Pessah, Cherednichenko & Lein, 2010; Wayman et al., 2012a; Wayman et al., 2012b), and these chemicals were detected in higher levels in brains of individuals with a syndromic form of autism (Mitchell et al., 2012). In addition, a study of exposure to traffic pollution, which involved examination of residential history of individuals and regional measurement of nitrogen dioxide and particulate matter, found an increased risk for autism among children exposed to the highest levels of pollution, even after controlling for ethnicity, parental education, smoking during pregnancy, or living in a densely populated region (Volk et al., 2012).
Recent studies of immigrant populations and autism risk have shown an elevated risk of having children with autism in these populations, suggesting that environmental factors associated with the migration, such as exposures and lifestyle, may play a role. A population-based study in the Netherlands suggested that immigrants have a higher risk of having a child with severely disabling autism (van der Ven et al., 2012), and another population-based study in Sweden suggested more specifically that immigrating to another country during pregnancy may increase the risk of having a child with autism (Magnusson et al., 2012).
One strategy for identifying environmental risk factors for ASD may be to focus on factors that converge on the same cellular signaling pathways as known ASD susceptibility genes (Pessah & Lein, 2008; Stamou et al., 2012). Genetic factors can amplify the effects of environmental exposures by disrupting the same signaling systems during critical periods of development. The task of detecting environmental risks can be facilitated by the use of analytic approaches that incorporate genetic information. This enables identification of those combinations of exposures and genes that confer the highest risk. The value of this approach in the field of autism was demonstrated this past year when researchers found evidence that vitamin use during the months before and after conception resulted in a protective effect that reduced ASD risk. This effect was found to be associated with maternal and child genes coding for one-carbon metabolism variants, which play a role in the body's ability to metabolize the vitamins (Schmidt et al., 2011). These findings, however, should be viewed as preliminary and must be replicated.
Finally, a 2012 meta-analysis of existing epidemiologic studies found evidence supporting an independent effect of advancing maternal age on ASD risk (Sandin et al., 2012). A similar 2011 analysis showed an association between paternal age and ASD risk (Hultman et al., 2012). Also, a series of studies confirmed the correlation between paternal age and de novo mutation rate (Neale et al., 2012; O'Roak et al., 2012b; Sanders et al., 2012) and showed that the majority of de novo ASD mutations are from the father's genome (Iossifov et al., 2012; O'Roak, 2012b). While a de novo mutation mechanism seems most important in driving associations between paternal age and autism risk, the mechanism behind the maternal age association remains unknown. Furthermore, the role that environmental factors may play as preceding causes or interacting factors in mechanisms mediated by de novo mutations, or in other causal mechanisms, is unknown.
What Gaps Have Emerged in the Past Two Years?
Environmental Risk Factors
Although the 2011 IACC Strategic Plan update reported that environmental research is an understudied area that has been given insufficient attention and requires heightened priority, there continues to be a need for significant attention to this area of research, with new insights about de novo mutations suggesting a potential link between environmental and genomic factors. Given the universe of potential environmental factors, one of the challenges is prioritizing candidate exposures and lifestyle factors that could potentially increase risk for autism. Prioritization can be based on: expert consensus (e.g., list of ten priority exposures developed in 2012) (Landrigan, Lambertini & Birnbaum, 2012); research findings pointing to windows of susceptibility, such as the preconception and prenatal periods; screening of exposures that converge on the same signaling pathways as ASD susceptibility genes; and a focus on replicated findings, such as studies explicitly designed to reveal exposures mediating the association between parental age and autism risk.
The challenges to accurately measuring exposures during critical time windows in development, which in some cases may be many years prior to diagnosis, are substantial. The 2012 NIEHS Strategic Plan includes exposure research as one of six major themes, and there is little doubt that innovations in biomarker-based exposure assessment would be helpful in the autism research field. In addition, reports of higher rates in specific immigrant communities suggest a new opportunity to study the role that environmental factors associated with migration may potentially play in elevating autism risk in specific populations (Dealberto, 2011; Haglund & Källén, 2011; Magnusson et al., 2012; van der Ven et al., 2012).
Rapid throughput, high-content screening technologies, which would allow researchers to rapidly analyze large numbers of samples for many different parameters at the same time, need to be developed, validated, and implemented for use in research on environmental factors that may play a role in human disorders. These technologies could be used, for example, to help identify the most potent chemical and/or biochemical agents that alter neuronal connectivity, synaptic structure, and plasticity (ability to adapt or change the strength of signals transmitted through the synapse) by interfering with signaling pathways implicated in autism and related disorders.
Integration of physiological, biochemical, and morphological analysis of neuronal and immunological cellular models is needed to better understand the underlying biology of ASD. These models should be based on cells derived using new techniques such as induced pluripotent stem cell (iPSC) technology (in which one type of adult cell, such as a skin cell, is first reprogrammed into a stem cell and then induced into a different type of cell, such as a neuron) or transdifferentiation technology (similar to iPSC technology, except that adult cells are directly reprogrammed into a different type of mature cell without having to go through the intermediate pluripotent stem cell stage). Furthermore, this research must be conducted on samples collected from patients that have been fully genotyped and deeply phenotyped (analyzed for both genetic makeup and observable traits) in order to understand gene-environment interactions and reveal exposure biomarkers.
Genetic Risk Factors
Given the high degree of genetic heterogeneity in ASD, a high priority should be placed on ascertaining family trios (two parents and one affected child) for comprehensive genomic analysis, including whole exome sequencing (sequencing of only the coding regions of DNA), copy number variant (CNV) studies, and sequencing of mutations in non-coding regions of DNA. The understanding of inherited genetic variation in ASD has been hampered by the lower effect size (the strength of the relationship between the genetic variation and the ASD phenotype) that is characteristic of research into rare and common genetic variants associated with ASD, as well as the need for very large patient cohorts. Successful studies of common inherited variation in conditions like schizophrenia point to the need for larger patient cohorts and very large-scale collaborative analyses.
Further, to understand the interplay of genetic susceptibility and environmental exposure, genomics data must be combined with exposure measures, and appropriate statistical methodologies must be developed and applied. Using this approach will require larger samples than those used for studies focused on detecting either genetic or environmental effects alone, so that small interactive effects will be able to be detected. Novel analytic approaches must also be developed to maximize accuracy in detecting effects when they exist.
Finally, as discussed in Question 2, studies have continued to document metabolic (e.g., oxidative stress, low glutathione levels, redox imbalances, mitochondrial dysfunction) and immune system abnormalities (e.g., anti-brain antibodies and dysregulated cytokine production) in individuals with ASD and, in some cases, in their mothers during gestation. Additional research should investigate when these abnormalities are present (e.g., at birth or acquired within the neonatal period) and whether they are related to risk for autism.
Celestino-Soper PB, Violante S, Crawford EL, Luo R, Lionel AC, Delaby E, Cai G, Sadikovic B, Lee K, Lo C, Gao K, Person RE, Moss TJ, German JR, Huang N, Shinawi M, Treadwell-Deering D, Szatmari P, Roberts W, Fernandez B, Schroer RJ, Stevenson RE, Buxbaum JD, Betancur C, Scherer SW, Sanders SJ, Geschwind DH, Sutcliffe JS, Hurles ME, Wanders RJ, Shaw CA, Leal SM, Cook EH Jr, Goin-Kochel RP, Vaz FM, Beaudet AL. A common X-linked inborn error of carnitine biosynthesis may be a risk factor for nondysmorphic autism. Proc Natl Acad Sci. 2012 May 22;109(21):7974-81. [PMID: 22566635]
Coe BP, Girirajan S, Eichler EE. The genetic variability and commonality of neurodevelopmental disease. Am J Med Genet C Semin Med Genet. 2012 May 15;160C(2):118-29. [PMID: 22499536]
Dealberto MJ. Prevalence of autism according to maternal immigrant status and ethnic origin. Acta Psychiatr Scand. 2011 May;123(5):339-48. [PMID: 21219265]
Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev. 2012 Jun;22(3):229-37. [PMID: 22463983]
Haglund NG, Källén KB. Risk factors for autism and Asperger syndrome. Perinatal factors and migration. Autism. 2011 Mar;15(2):163-83. [PMID: 20923887]
Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, Miller J, Fedele A, Collins J, Smith K, Lotspeich L, Croen LA, Ozonoff S, Lajonchere C, Grether JK, Risch N. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011 Nov;68(11):1095-102. [PMID: 21727249]
Hultman CM, Sandin S, Levine SZ, Lichtenstein P, Reichenberg A. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry. 2011 Dec;16(12):1203-12. [PMID:21116277]
Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, Yamrom B, Lee YH, Narzisi G, Leotta A, Kendall J, Grabowska E, Ma B, Marks S, Rodgers L, Stepansky A, Troge J, Andrews P, Bekritsky M, Pradhan K, Ghiban E, Kramer M, Parla J, Demeter R, Fulton LL, Fulton RS, Magrini VJ, Ye K, Darnell JC, Darnell RB, Mardis ER, Wilson RK, Schatz MC, McCombie WR, Wigler M. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012 Apr 26;74(2):285-99. [PMID: 22542183]
Landrigan PJ, Lambertini L, Birnbaum LS. A research strategy to discover the environmental causes of autism and neurodevelopmental disabilities. Environ Health Perspect. 2012 Jul;120(7):a258-60. [PMID: 22543002]
Magnusson C, Rai D, Goodman A, Lundberg M, Idring S, Svensson A, Koupil I, Serlachius E, Dalman C. Migration and autism spectrum disorder: population-based study. Br J Psychiatry. 2012 Aug;201:109-15. [PMID: 22361019]
Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012 Mar 16;148(6):1223-41. [PMID: 22424231]
Mitchell MM, Woods R, Chi LH, Schmidt RJ, Pessah IN, Kostyniak PJ, Lasalle JM. Levels of select PCB and PBDE congeners in human postmortem brain reveal possible environmental involvement in 15q11-q13 duplication autism spectrum disorder. Environ Mol Mutagen. 2012 Oct;53(8):589-98. [PMID: 22930557]
Neale BM, Kou Y, Liu L, Ma'ayan A, Samocha KE, Sabo A, Lin CF, Stevens C, Wang LS, Makarov V, Polak P, Yoon S, Maguire J, Crawford EL, Campbell NG, Geller ET, Valladares O, Schafer C, Liu H, Zhao T, Cai G, Lihm J, Dannenfelser R, Jabado O, Peralta Z, Nagaswamy U, Muzny D, Reid JG, Newsham I, Wu Y, Lewis L, Han Y, Voight BF, Lim E, Rossin E, Kirby A, Flannick J, Fromer M, Shakir K, Fennell T, Garimella K, Banks E, Poplin R, Gabriel S, DePristo M, Wimbish JR, Boone BE, Levy SE, Betancur C, Sunyaev S, Boerwinkle E, Buxbaum JD, Cook EH Jr, Devlin B, Gibbs RA, Roeder K, Schellenberg GD, Sutcliffe JS, Daly MJ. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012 Apr 4;485(7397):242-5. [PMID: 22495311]
Novarino G, El-Fishawy P, Kayserili H, Meguid NA, Scott EM, Schroth J, Silhavy JL, Kara M, Khalil RO, Ben-Omran T, Ercan-Sencicek AG, Hashish AF, Sanders SJ, Gupta AR, Hashem HS, Matern D, Gabriel S, Sweetman L, Rahimi Y, Harris RA, State MW, Gleeson JG. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science. 2012 Oct 19;338(6105):394-7. [PMID: 22956686]
O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, Carvill G, Kumar A, Lee C, Ankenman K, Munson J, Hiatt JB, Turner EH, Levy R, O'Day DR, Krumm N, Coe BP, Martin BK, Borenstein E, Nickerson DA, Mefford HC, Doherty D, Akey JM, Bernier R, Eichler EE, Shendure J. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012 Dec 21;338(6114):1619-22. [PMID: 23160955]
O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee C, Smith JD, Turner EH, Stanaway IB, Vernot B, Malig M, Baker C, Reilly B, Akey JM, Borenstein E, Rieder MJ, Nickerson DA, Bernier R, Shendure J, Eichler EE. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature. 2012 Apr 4;485(7397):246-50. [PMID: 22495309]
Ozonoff S, Young GS, Carter A, Messinger D, Yirmiya N, Zwaigenbaum L, Bryson S, Carver LJ, Constantino JN, Dobkins K, Hutman T, Iverson JM, Landa R, Rogers SJ, Sigman M, Stone WL. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics. 2011 Sep;128(3):e488-95. [PMID: 21844053]
Pessah IN, Cherednichenko G, Lein PJ. Minding the calcium store: ryanodine receptor activation as a convergent mechanism of PCB toxicity. Pharmacol Ther. 2010 Feb;125(2):260-85. [PMID: 19931307]
Pessah IN, Lein P. (2008). Evidence for Environmental Susceptibility in Autism. What we know What We Need to Know About Gene x Environment Interactions. In AW Zimmerman (Ed.), Autism: Current Theories and Evidence (Chapter 19). Totowa, NJ: Humana Press.
Roberts EM, English PB, Grether JK, Windham GC, Somberg L, Wolff C. Maternal residence near agricultural pesticide applications and autism spectrum disorders among children in the California Central Valley. Environ Health Perspect. 2007 Oct;115(10):1482-9. [PMID: 17938740]
Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, Walker MF, Ober GT, Teran NA, Song Y, El-Fishawy P, Murtha RC, Choi M, Overton JD, Bjornson RD, Carriero NJ, Meyer KA, Bilguvar K, Mane SM, Sestan N, Lifton RP, Günel M, Roeder K, Geschwind DH, Devlin B, State MW. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature. 2012 Apr 4;485(7397):237-41. [PMID: 22495306]
Sandin S, Hultman CM, Kolevzon A, Gross R, MacCabe JH, Reichenberg A. Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2012 May;51(5):477-486.e1. [PMID: 22525954]
Schmidt RJ, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tancredi DJ, Tassone F, Hertz-Picciotto I. Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. Epidemiology. 2011 Jul;22(4):476-85. [PMID: 21610500]
Shelton JF, Hertz-Picciotto I, Pessah IN. Tipping the balance of autism risk: potential mechanisms linking pesticides and autism. Environ Health Perspect. 2012 Jul;120(7):944-51. [PMID: 22534084]
Stamou M, Streifel KM, Goines PE, Lein PJ. Neuronal connectivity as a convergent target of gene-environment interactions that confer risk for autism spectrum disorders. Neurotoxicol Teratol. 2012 Dec 23. [Epub ahead of print] [PMID: 23269408]
van der Ven E, Termorshuizen F, Laan W, Breetvelt EJ, van Os J, Selten JP. An incidence study of diagnosed autism-spectrum disorders among immigrants to the Netherlands. Acta Psychiatr Scand. 2012 Dec 9. [PMID: 23216206]
Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet. 2012 Jul 18;13(8):565-75. [PMID: 22805709]
Volk H, Lurmann F, Penfold B, Hertz-Picciotto I, McConnell R. Traffic related air pollution, particulate matter, and autism. JAMA Psychiatry. 2013;70(1):71-77.
Wayman GA, Bose DD, Yang D, Lesiak A, Bruun D, Impey S, Ledoux V, Pessah IN, Lein PJ. PCB-95 modulates the calcium-dependent signaling pathway responsible for activity-dependent dendritic growth. Environ Health Perspect. 2012 Jul;120(7):1003-9. [PMID: 22534176]
Wayman GA, Yang D, Bose DD, Lesiak A, Ledoux V, Bruun D, Pessah IN, Lein PJ. PCB-95 promotes dendritic growth via ryanodine receptor-dependent mechanisms. Environ Health Perspect. 2012 Jul;120(7):997-1002. [PMID: 22534141]
Zoghbi HY, Bear MF. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb Perspect Biol. 2012 Mar 1;4(3). [PMID: 22258914]
All material appearing in this report is in the public domain and may be reproduced or copied. A suggested citation follows.
Interagency Autism Coordinating Committee (IACC). IACC Strategic Plan for Autism Spectrum Disorder (ASD) Research —2012 Update. December 2012. Retrieved from the U.S. Department of Health and Human Services Interagency Autism Coordinating Committee website: http://iacc.hhs.gov/strategic-plan/2012/index.shtml